Candesartan cilexetil

Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg An angiotensin II receptor antagonist.

Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg An angiotensin II receptor antagonist.

Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg An angiotensin II receptor antagonist.

InformationCandesartan Cilexetil Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.In vitroCandesartan blocks the effects of angiotensin II at the angiotensin II type

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

General description Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Candesartan

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.

A prodrug of the potent, long-acting, and selective AT1 receptor antagonist, candesartan 4-16 mg/day effectively reduces diastolic blood pressure and has proved useful in the treatment of hypertension and diabetes.